Experience with basiliximab in pediatric renal transplantation.
Vilalta
R
R
Department of Nephrology-Hemodialysis, Hospital Materno-infantil Vall d'Hebron, Barcelona, Spain.
Vila
A
A
Nieto
J
J
Espanol
T
T
Caragol
I
I
Callís
L
L
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D002648:Child; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007518:Isoantibodies / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000032:analysis; D011993:Recombinant Fusion Proteins; D006435:Renal Dialysis; D012086:Reoperation; D013997:Time Factors
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D008775:Methylprednisolone